Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Novartis Q3 Adj. EPS $2.25, Inline, Sales $13.909B Miss $14.105B Estimate

Author: Benzinga Newsdesk | October 28, 2025 01:56am
Novartis (NYSE:NVS) reported quarterly earnings of $2.25 per share which met the analyst consensus estimate. This is a 9.22 percent increase over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $13.909 billion which missed the analyst consensus estimate of $14.105 billion by 1.39 percent. This is a 8.47 percent increase over sales of $12.823 billion the same period last year.

Posted In: NVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist